MXPA04003506A - Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn. - Google Patents

Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.

Info

Publication number
MXPA04003506A
MXPA04003506A MXPA04003506A MXPA04003506A MXPA04003506A MX PA04003506 A MXPA04003506 A MX PA04003506A MX PA04003506 A MXPA04003506 A MX PA04003506A MX PA04003506 A MXPA04003506 A MX PA04003506A MX PA04003506 A MXPA04003506 A MX PA04003506A
Authority
MX
Mexico
Prior art keywords
crohn
disease
treatment
pharmaceutical composition
ulcerative colitis
Prior art date
Application number
MXPA04003506A
Other languages
English (en)
Inventor
Kluever Jepsen Svenn
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MXPA04003506A publication Critical patent/MXPA04003506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

La presente invencion concierne a un nuevo metodo de preparacion de granulos que contienen acido 5-aminosalicilico, y a un nuevo metodo de preparacion de una composicion farmaceutica oral para el tratamiento de la colitis ulcerativa o de la enfermedad de Crohn, que comprende como ingrediente activo acido 5-aminosalicilico, el metodo comprende la granulacion con agua como un solvente.
MXPA04003506A 2001-10-15 2001-10-15 Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn. MXPA04003506A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2001/000677 WO2003032952A1 (en) 2001-10-15 2001-10-15 Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease

Publications (1)

Publication Number Publication Date
MXPA04003506A true MXPA04003506A (es) 2004-07-23

Family

ID=8149447

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003506A MXPA04003506A (es) 2001-10-15 2001-10-15 Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.

Country Status (15)

Country Link
EP (1) EP1441700B1 (es)
JP (1) JP4726414B2 (es)
KR (1) KR100859358B1 (es)
CN (1) CN100506234C (es)
AT (1) ATE371441T1 (es)
CA (1) CA2462905C (es)
DE (1) DE60130270T2 (es)
DK (1) DK1441700T3 (es)
ES (1) ES2288999T3 (es)
HK (1) HK1068282A1 (es)
IL (2) IL161193A0 (es)
MX (1) MXPA04003506A (es)
NO (1) NO335042B1 (es)
PT (1) PT1441700E (es)
WO (1) WO2003032952A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
JP2007523664A (ja) 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
EP1470819A1 (en) * 2003-04-23 2004-10-27 Ferring B.V. High drug load mesalazine sachet
EP1547601A1 (en) * 2003-12-23 2005-06-29 Ferring B.V. Coating method
DE602005013098D1 (de) * 2004-09-01 2009-04-16 Procter & Gamble Zusammensetzungen mit 5-amino-2-hydroxybenzoesäure und einem reduzierendem zucker
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
AU2011300642B2 (en) * 2010-09-10 2015-02-26 Pharmazell Gmbh Process for producing crystalline 5-aminosalicylic acid
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
WO2015193788A1 (en) * 2014-06-16 2015-12-23 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
ITUA20162293A1 (it) * 2016-04-05 2017-10-05 Sofar Spa Processo per formulazioni solide di mesalazina
JP2017189121A (ja) * 2016-04-11 2017-10-19 国立大学法人旭川医科大学 抗ＴＮＦα抗体適応疾患の治療における抗ＴＮＦα抗体投与時反応の発症リスクを判定する方法、並びに該判定用オリゴヌクレオチドキット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (es) * 1980-03-20 1982-03-11
JPH0334928A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与製剤
DE871434T1 (de) * 1995-12-21 2001-04-05 Farmaceutisk Lab Ferring As Va 5-asa enthaltendes orales arzneimittel mit modifizierter freisetzung sowie verfahren zur behandlung von darmerkrankungen
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.

Also Published As

Publication number Publication date
JP2005509619A (ja) 2005-04-14
ATE371441T1 (de) 2007-09-15
IL161193A0 (en) 2004-08-31
CA2462905A1 (en) 2003-04-24
ES2288999T3 (es) 2008-02-01
EP1441700A1 (en) 2004-08-04
CN100506234C (zh) 2009-07-01
NO20042011L (no) 2004-06-30
PT1441700E (pt) 2007-10-29
EP1441700B1 (en) 2007-08-29
KR20040047906A (ko) 2004-06-05
CA2462905C (en) 2011-04-12
CN1558752A (zh) 2004-12-29
DE60130270T2 (de) 2008-05-29
NO335042B1 (no) 2014-09-01
JP4726414B2 (ja) 2011-07-20
IL161193A (en) 2010-05-31
DE60130270D1 (de) 2007-10-11
HK1068282A1 (en) 2005-04-29
WO2003032952A1 (en) 2003-04-24
DK1441700T3 (da) 2007-10-08
KR100859358B1 (ko) 2008-09-22

Similar Documents

Publication Publication Date Title
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
WO2001085212A3 (en) Drug delivery systems for photodynamic therapy
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
FI20011852A (fi) Menetelmä fluoksetiinia tai sen happoadditiosuolaa sisältävän dispergoituvan tabletin valmistamiseksi
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
TW200503782A (en) New formulations and use thereof
TR200200716T2 (tr) Ketiyapin granülleri
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2001068676A3 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel
GEP20043377B (en) Pharmaceutical Complex
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
WO2004078761A8 (en) Enantiomerically pure cilazapril,process for preparation
NZ532449A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and Crohn's disease
PL369504A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
UY27472A1 (es) Metodo para la preparación de una composición farmacéutica que comprende un acido-5-amino-salicilico, para uso en el tratamiento de la colitis ulcerosa y enfermedad de crohn.

Legal Events

Date Code Title Description
FG Grant or registration